학술논문
Managing hyperglycemia and rash associated with alpelisib: expert consensus recommendations using the Delphi technique.
Document Type
article
Author
Gallagher, Emily; Moore, Heather; Lacouture, Mario; Dent, Susan; Farooki, Azeez; Goncalves, Marcus; Isaacs, Claudine; Johnston, Abigail; Juric, Dejan; Quandt, Zoe; Spring, Laura; Berman, Brian; Decker, Melanie; Hortobagyi, Gabriel; Kaffenberger, Benjamin; Kwong, Bernice; Pluard, Timothy; Rao, Ruta; Schwartzberg, Lee; Broder, Michael
Source
npj Breast Cancer. 10(1)
Subject
Language
Abstract
Hyperglycemia and rash are expected but challenging adverse events of phosphatidylinositol-3-kinase inhibition (such as with alpelisib). Two modified Delphi panels were conducted to provide consensus recommendations for managing hyperglycemia and rash in patients taking alpelisib. Experts rated the appropriateness of interventions on a 1-to-9 scale; median scores and dispersion were used to classify the levels of agreement. Per the hyperglycemia panel, it is appropriate to start alpelisib in patients with HbA1c 6.5% (diabetes) to